



(11)

EP 2 694 972 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
G01N 33/574 (2006.01)

(86) International application number:
PCT/US2012/032206

(48) Corrigendum issued on:
16.08.2017 Bulletin 2017/33

(87) International publication number:
WO 2012/138785 (11.10.2012 Gazette 2012/41)

(45) Date of publication and mention
of the grant of the patent:
21.06.2017 Bulletin 2017/25

(21) Application number: **12716858.1**

(22) Date of filing: **04.04.2012**

(54) **METHODS FOR PREDICTING AND IMPROVING THE SURVIVAL OF GASTRIC CANCER PATIENTS**

VERFAHREN ZUR VORHERSAGE UND VERBESSERUNG DER ÜBERLEBENSZEIT VON
MAGENKREBSPATIENTEN

PROCÉDÉS POUR PRÉDIRE ET AMÉLIORER LA SURVIE DE PATIENTS ATTEINTS DE CANCER
GASTRIQUE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(74) Representative: **J A Kemp**
14 South Square
Gray's Inn
London WC1R 5JJ (GB)

(30) Priority: **04.04.2011 US 201161471678 P**
25.01.2012 US 201261590787 P

(56) References cited:
WO-A1-2011/008990

(43) Date of publication of application:
12.02.2014 Bulletin 2014/07

• **BACHLEITNER-HOFMANN T. ET AL.:**
"Stimulation of epidermal growth factor (EGFR)
or HER-3 mediates resistance to MET tyrosine
kinase inhibition in MET-amplified gastric cancer
cells", PROC. AM. ASS. CANCER RES. ANN.
MEETING, vol. 49, April 2008 (2008-04), page
1186, XP002678285, & 99TH ANNUAL MEETING
OF THE
AMERICAN-ASSOCIATION-FOR-CANCER-RESE
ARCH; SAN DIEGO, CA, USA; APRIL 12 -16, 2008

(73) Proprietor: **Pierian Holdings, Inc.**
Franklin, TN 37067 (US)

(72) Inventors:
• **KIM, Phillip**
Irvine, CA 92612 (US)
• **SINGH, Sharat**
Rancho Santa Fe, CA 92127 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 694 972 B8

- BACHLEITNER-HOFMANN T. ET AL.: "Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET inhibition", CLIN. CANCER RES., vol. 17, no. 1, 1 January 2011 (2011-01-01), pages 122-133, XP55030286,
- MUKOHARA T. ET AL.: "Foretinib (GSK1363089) inhibits growth of gastric cancer cell lines through blockade of inter-receptor tyrosine kinases networks", EUR. J. CANCER, vol. 8, no. 7, #109, November 2010 (2010-11), page 42, XP027497797,
- TABERNERO J. ET AL.: "Integration of targeted therapies", EUR. J. CANCER, vol. 7, no. 2, #305, September 2009 (2009-09), page 74, XP026689064,
- BACHLEITNER-HOFMANN T. ET AL.: "HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells", MOL. CANCER THER., vol. 7, no. 11, November 2008 (2008-11), pages 3499-3508, XP55020686,
- CORSO S. ET AL.: "Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition", MOL. CANCER, vol. 9, no. 1, 26 May 2010 (2010-05-26), page 121, XP021077869,
- PENTHEROUDAKIS G. ET AL.: "Incorporation of Targeted Agents in the Management of Patients with Advanced Gastric Cancer", CURR. MED. CHEM., vol. 18, no. 11, 1 April 2011 (2011-04-01), pages 1629-1639, XP002678286,
- KIM P. ET AL.: "Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients", PROTEOME SCIENCE, vol. 9, no. 1, 15 December 2011 (2011-12-15), page 75, XP55030160,